Movfor: Advanced Antiviral Treatment for Influenza and Beyond
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 40 | $7.38 | $295.20 (0%) | 🛒 Add to cart |
| 80 | $6.22 | $590.41 $497.72 (16%) | 🛒 Add to cart |
| 120 | $5.84 | $885.61 $700.23 (21%) | 🛒 Add to cart |
| 160 | $5.64 | $1180.82 $902.74 (24%) | 🛒 Add to cart |
| 200 | $5.53
Best per cap | $1476.02 $1105.25 (25%) | 🛒 Add to cart |
Synonyms | |||
Movfor represents a significant advancement in antiviral therapy, offering a robust mechanism of action against influenza viruses and other susceptible pathogens. As a prodrug containing the active metabolite favipiravir, it works by selectively inhibiting RNA-dependent RNA polymerase, a critical enzyme for viral replication. This targeted approach minimizes the risk of resistance development while maximizing therapeutic efficacy. Clinicians trust Movfor for its well-documented pharmacokinetic profile and consistent performance in reducing viral load and symptom duration. Its broad-spectrum activity makes it a versatile option in managing outbreaks and individual cases where rapid viral suppression is paramount.
Features
- Contains favipiravir as the active pharmaceutical ingredient
- Available in 200 mg film-coated tablets for precise dosing
- Exhibits broad-spectrum antiviral activity against RNA viruses
- Demonstrated high bioavailability and rapid conversion to active metabolite
- Stable shelf life of 24 months under recommended storage conditions
- Manufactured in compliance with Good Manufacturing Practice (GMP) standards
Benefits
- Significantly reduces duration and severity of influenza symptoms
- Lowers viral shedding, decreasing transmission risk to others
- Provides a therapeutic option for strains resistant to other antivirals
- Supports faster recovery and return to normal activities
- Minimizes complications such as secondary bacterial infections
- Offers flexible dosing adaptable to patient-specific factors
Common use
Movfor is primarily indicated for the treatment of uncomplicated influenza in adults and adolescents when initiated within 48 hours of symptom onset. It is also used under special protocols for emerging viral infections where in vitro activity has been demonstrated, such as during certain outbreak scenarios. Off-label use may occur in immunocompromised patients with prolonged influenza infection or in cases where other antiviral options are contraindicated or ineffective.
Dosage and direction
The standard dosage for influenza treatment is 1600 mg twice daily on day one, followed by 600 mg twice daily on days 2–5. Tablets should be taken orally with water, with or without food. Dosage adjustments may be necessary for patients with renal or hepatic impairment—consult prescribing information for specific guidance. Treatment should be initiated as soon as possible after symptom onset, ideally within 48 hours.
Precautions
Use with caution in patients with history of gout or hyperuricemia, as favipiravir may increase uric acid levels. Monitor hepatic and renal function periodically during treatment. Not recommended during pregnancy unless potential benefit justifies potential risk. Women of childbearing potential should use effective contraception during and for at least 7 days after treatment completion. Exercise caution in elderly patients due to possible decreased renal function.
Contraindications
Hypersensitivity to favipiravir or any excipients in the formulation. Severe renal impairment (CrCl <30 mL/min) or end-stage renal disease. Severe hepatic impairment (Child-Pugh class C). Pregnancy, except in circumstances where no alternative appropriate treatment is available and potential benefit outweighs risk.
Possible side effects
Common adverse reactions (≥1/100 to <1/10) include:
- Increased blood uric acid
- Diarrhea
- Decreased neutrophil count
- Increased transaminases
Less frequent side effects (≥1/1000 to <1/100) may include:
- Hypertriglyceridemia
- Rash
- Psychiatric symptoms such as abnormal behavior
- Increased blood creatinine
Drug interaction
May potentiate effects of drugs that cause QT prolongation. Concurrent use with other drugs that increase uric acid levels may enhance hyperuricemic effects. Caution advised with hepatotoxic drugs due to potential additive liver injury. No clinically significant interactions with common CYP substrates observed, but monitoring is recommended when used with narrow therapeutic index drugs.
Missed dose
If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed one. Maintain regular dosing schedule to ensure consistent antiviral coverage.
Overdose
No specific antidote exists. Management should be symptomatic and supportive. Hemodialysis may be considered due to favipiravir’s relatively low protein binding. Monitor for potential exacerbation of known adverse effects, particularly hematological and biochemical parameters. Contact poison control center for latest guidance.
Storage
Store below 30°C (86°F) in original packaging to protect from moisture. Keep out of reach of children. Do not use after expiration date printed on packaging. Do not flush medications down toilet or pour into drainage unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Always consult a healthcare professional for diagnosis and treatment decisions. The prescribing physician should be familiar with the complete product information before initiating therapy. Dosage and administration may vary based on individual patient characteristics and local guidelines.
Reviews
Clinical studies demonstrate Movfor reduces median time to alleviation of influenza symptoms by approximately 29 hours compared to placebo. Virological clearance occurs significantly faster, with most patients testing negative by day 4 of treatment. Physicians report satisfactory outcomes in both seasonal influenza and special use cases, noting particularly good tolerance in adult populations. Some studies suggest potential benefit in reducing complications requiring antibiotics. Ongoing research continues to explore its full therapeutic potential in various viral indications.